SG10201502391WA - Compound for treatment of respiratory condition or disease - Google Patents

Compound for treatment of respiratory condition or disease

Info

Publication number
SG10201502391WA
SG10201502391WA SG10201502391WA SG10201502391WA SG10201502391WA SG 10201502391W A SG10201502391W A SG 10201502391WA SG 10201502391W A SG10201502391W A SG 10201502391WA SG 10201502391W A SG10201502391W A SG 10201502391WA SG 10201502391W A SG10201502391W A SG 10201502391WA
Authority
SG
Singapore
Prior art keywords
disease
compound
treatment
respiratory condition
respiratory
Prior art date
Application number
SG10201502391WA
Other languages
English (en)
Inventor
John Nicholas Lambert
Jane Ryan
Janet Marie Wilson
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of SG10201502391WA publication Critical patent/SG10201502391WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201502391WA 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease SG10201502391WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease

Publications (1)

Publication Number Publication Date
SG10201502391WA true SG10201502391WA (en) 2015-05-28

Family

ID=44788654

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012073565A SG184430A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease
SG10201502391WA SG10201502391WA (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012073565A SG184430A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Country Status (16)

Country Link
US (1) US20110257192A1 (enExample)
EP (1) EP2558097B1 (enExample)
JP (1) JP6148618B2 (enExample)
KR (1) KR20130106267A (enExample)
CN (2) CN102844032A (enExample)
AU (1) AU2011241478B2 (enExample)
BR (1) BR112012026244A2 (enExample)
CA (1) CA2796207A1 (enExample)
EA (1) EA025224B1 (enExample)
ES (1) ES2647223T3 (enExample)
IL (1) IL222244A0 (enExample)
MX (1) MX2012011938A (enExample)
NZ (1) NZ603040A (enExample)
SG (2) SG184430A1 (enExample)
WO (1) WO2011127538A1 (enExample)
ZA (1) ZA201207696B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229140B (zh) 2013-04-12 2022-06-10 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
US9802926B2 (en) 2014-06-20 2017-10-31 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
DE602004014728D1 (de) * 2003-02-21 2008-08-14 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
WO2006029182A2 (en) * 2004-09-07 2006-03-16 The La Jolla Institute For Molecular Medicine Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2725618C (en) * 2008-05-27 2016-04-12 Biota Scientific Management Pty Ltd Antiviral salts
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
MX2012011938A (es) 2013-01-28
ZA201207696B (en) 2014-03-26
EA201201416A1 (ru) 2013-03-29
US20110257192A1 (en) 2011-10-20
WO2011127538A1 (en) 2011-10-20
NZ603040A (en) 2015-03-27
AU2011241478A1 (en) 2012-11-01
AU2011241478B2 (en) 2016-12-01
SG184430A1 (en) 2012-11-29
EP2558097A4 (en) 2013-09-11
ES2647223T3 (es) 2017-12-20
IL222244A0 (en) 2012-12-31
JP6148618B2 (ja) 2017-06-14
EP2558097A1 (en) 2013-02-20
CN105560245A (zh) 2016-05-11
KR20130106267A (ko) 2013-09-27
JP2013523844A (ja) 2013-06-17
BR112012026244A2 (pt) 2016-07-12
CA2796207A1 (en) 2011-10-20
EA025224B1 (ru) 2016-12-30
EP2558097B1 (en) 2017-10-25
CN102844032A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
ZA201205829B (en) Treatment of respiratory disorders
IL230458A0 (en) Compounds for the treatment and prevention of respiratory syncytial viral disease
ZA201304280B (en) Treatment of jak2-mediated conditions
ZA201301601B (en) Treatment of diseases
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2638389A4 (en) TREATMENT OF EXTRACTION OF RENEWAL
GB201002243D0 (en) Respiratory disease treatment
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
GB201002224D0 (en) Respiratory disease treatment
IL217185A0 (en) Medicinal carbohydrates for treatment of respiratory conditions
ZA201207696B (en) Compound for treatment of respiratory condition or disease
ZA201103007B (en) Treatment of tantalium-and/or niobium-containing compounds
HK1182325A (en) Compound for treatment of respiratory condition or disease
PL2456445T3 (pl) Środek do leczenia chorób skóry
AU2010901601A0 (en) Compound for the treatment of respiratory condition or disease
GB201001893D0 (en) Respiratory disease treatment
GB201002235D0 (en) Respiratory disease treatment
GB201001903D0 (en) Respiratory disease treatment
GB201002841D0 (en) Treatment of inflammatory respiratory disease
GB201001912D0 (en) Treatment of respiratory disorders
GB201009094D0 (en) Compounds for the treatment of closridium difficile-associated disease
GB201101770D0 (en) Treatment of inflammatory respiratory disease
EG26997A (en) Tube for treatment of syrngomylia